CEO SUMMARY: Congressional lawmakers and the federal Food and Drug Administration are again eyeing changes that would bring greater oversight to laboratory-developed tests (LDTs). Leaders at clinical laboratories and pathology groups should monitor these proposals, both of which could have long-term ramifications for labs that use LDTs. Action to increase regulatory oversight of laboratory-developed testsĀ (LDTs) […]
To access this post, you must purchase The Dark Report.